Palisade Bio Inc - Asset Resilience Ratio
Palisade Bio Inc (PALI) has an Asset Resilience Ratio of 0.27% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Palisade Bio Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2020)
This chart shows how Palisade Bio Inc's Asset Resilience Ratio has changed over time. See Palisade Bio Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Palisade Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Palisade Bio Inc (PALI) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $21.00K | 0.27% |
| Total Liquid Assets | $21.00K | 0.27% |
Asset Resilience Insights
- Limited Liquidity: Palisade Bio Inc maintains only 0.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Palisade Bio Inc Industry Peers by Asset Resilience Ratio
Compare Palisade Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
Annual Asset Resilience Ratio for Palisade Bio Inc (2014–2020)
The table below shows the annual Asset Resilience Ratio data for Palisade Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.53% | $16.00K | $3.02 Million | -35.48pp |
| 2017-12-31 | 36.01% | $5.00 Million | $13.88 Million | +13.89pp |
| 2016-12-31 | 22.12% | $5.00 Million | $22.60 Million | -28.17pp |
| 2015-12-31 | 50.29% | $7.52 Million | $14.95 Million | 0.00pp |
| 2014-12-31 | 50.29% | $15.01 Million | $29.84 Million | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more